These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34749675)

  • 41. Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.
    Palanee-Phillips T; Schwartz K; Brown ER; Govender V; Mgodi N; Kiweewa FM; Nair G; Mhlanga F; Siva S; Bekker LG; Jeenarain N; Gaffoor Z; Martinson F; Makanani B; Naidoo S; Pather A; Phillip J; Husnik MJ; van der Straten A; Soto-Torres L; Baeten J
    PLoS One; 2015; 10(6):e0128857. PubMed ID: 26061040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Action of the Dapivirine Vaginal Ring as Understood by Women Participating in an Open Label Extension Study.
    Naidoo K; T ME; Katz AW; Morgan G; Krishnaveni R; Lydia ST; Sarita N; Leila ME
    AIDS Behav; 2023 Jan; 27(1):75-81. PubMed ID: 35672549
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls.
    Farr Zuend C; Noël-Romas L; Hoger S; McCorriser S; Westmacott G; Marrazzo J; Hillier SL; Dezzutti C; Squires K; Bunge KE; Burgener A
    AIDS; 2021 Mar; 35(3):369-380. PubMed ID: 33181534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Men's Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and Zimbabwe.
    Montgomery ET; Katz AWK; Duby Z; Mansoor LE; Morar NS; Naidoo K; Tsidya M; Chitukuta M; Guma V; Tenza S; Leslie J; Garcia M; Naidoo S
    AIDS Behav; 2021 Jun; 25(6):1890-1900. PubMed ID: 33389318
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Using Emoji Stickers to Understand End-User Opinions of the Dapivirine Vaginal Ring for HIV Prevention.
    Katz AWK; Mansoor LE; Tsidya M; Mathebula F; Singh D; Siva S; Akello C; Chitowa TH; Garcia M; Soto-Torres L; Montgomery ET
    AIDS Behav; 2021 Dec; 25(12):3955-3966. PubMed ID: 34180041
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brief Report: Anal Intercourse, HIV-1 Risk, and Efficacy in a Trial of a Dapivirine Vaginal Ring for HIV-1 Prevention.
    Peebles K; van der Straten A; Palanee-Phillips T; Reddy K; Hillier SL; Hendrix CW; Harkoo I; Gati Mirembe B; Jeenarain N; Baeten JM; Brown ER;
    J Acquir Immune Defic Syndr; 2020 Mar; 83(3):197-201. PubMed ID: 31809308
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of dapivirine vaginal ring for HIV prevention.
    Devlin B; Nuttall J; Wilder S; Woodsong C; Rosenberg Z
    Antiviral Res; 2013 Dec; 100 Suppl():S3-8. PubMed ID: 24188702
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.
    Nel A; van Niekerk N; Kapiga S; Bekker LG; Gama C; Gill K; Kamali A; Kotze P; Louw C; Mabude Z; Miti N; Kusemererwa S; Tempelman H; Carstens H; Devlin B; Isaacs M; Malherbe M; Mans W; Nuttall J; Russell M; Ntshele S; Smit M; Solai L; Spence P; Steytler J; Windle K; Borremans M; Resseler S; Van Roey J; Parys W; Vangeneugden T; Van Baelen B; Rosenberg Z;
    N Engl J Med; 2016 Dec; 375(22):2133-2143. PubMed ID: 27959766
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania.
    Tubert J; Packel L; Hunter LA; Mfaume R; Njau P; Ramadhani AA; Liu JX; McCoy SI
    AIDS Res Ther; 2021 Apr; 18(1):21. PubMed ID: 33902623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial.
    Mirembe BG; Cabrera MV; van der Straten A; Nakalega R; Cobbing M; Mgodi NM; Palanee-Phillips T; Mayo AJ; Dadabhai S; Mansoor LE; Siva S; Nair G; Chinula L; Akello CA; Nakabiito C; Soto-Torres LE; Baeten JM; Brown ER
    AIDS Behav; 2023 Mar; 27(3):1030-1043. PubMed ID: 36066762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women.
    Shapley-Quinn MK; Laborde N; Luecke E; Hoesley C; Salata RA; Johnson S; Nel A; Soto-Torres L; Chen BA; van der Straten A
    AIDS Patient Care STDS; 2022 Mar; 36(3):97-105. PubMed ID: 35289688
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa.
    Chitukuta M; Duby Z; Katz A; Nakyanzi T; Reddy K; Palanee-Phillips T; Tembo T; Etima J; Musara P; Mgodi NM; van der Straten A;
    Cult Health Sex; 2019 Nov; 21(11):1209-1224. PubMed ID: 30657023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acceptability of the Dapivirine Vaginal Ring and Oral Truvada Among African Users in Late-Stage of Pregnancy.
    Montgomery ET; Hawley I; Fairlie L; Bunge K; Mathebula F; Etima J; Mutero P; Senyama L; Mayo A; Stoner MCD; Piper J; Balan I; van der Straten A
    AIDS Behav; 2024 Mar; 28(3):963-973. PubMed ID: 37932492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence.
    Spence P; Nel A; van Niekerk N; Derrick T; Wilder S; Devlin B
    J Pharm Biomed Anal; 2016 Jun; 125():94-100. PubMed ID: 27016673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Qualitative Perceptions of Dapivirine VR Adherence and Drug Level Feedback Following an Open-Label Extension Trial.
    Naidoo K; Mansoor LE; Katz AWK; Garcia M; Kemigisha D; Morar NS; Zimba CC; Chitukuta M; Reddy K; Soto-Torres L; Naidoo S; Montgomery ET
    J Acquir Immune Defic Syndr; 2021 Apr; 86(4):e90-e96. PubMed ID: 33278181
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Attitudes and perceptions towards novel objective measures of ARV-based vaginal ring use: Results from a global stakeholder survey.
    Stalter RM; Tharaldson J; Owen DH; Okumu E; Moench T; Mack N; Tolley EE; MacQueen KM
    PLoS One; 2017; 12(7):e0180963. PubMed ID: 28708847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
    Bhavaraju N; Shears K; Schwartz K; Mullick S; Jeckonia P; Murungu J; Persaud U; Vij A; Torjesen K
    Curr HIV/AIDS Rep; 2021 Dec; 18(6):508-517. PubMed ID: 34910276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States.
    van der Straten A; Panther L; Laborde N; Hoesley CJ; Cheng H; Husnik MJ; Horn S; Nel A; Soto-Torres L; Chen BA
    AIDS Behav; 2016 Nov; 20(11):2644-2653. PubMed ID: 26837628
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The relationship between vaginal ring use and intimate partner violence and social harms: formative research outcomes from the CHARISMA study in Johannesburg, South Africa.
    Hartmann M; Palanee-Phillips T; O'Rourke S; Adewumi K; Tenza S; Mathebula F; Wagner D; Ayub A; Montgomery ET
    AIDS Care; 2019 Jun; 31(6):660-666. PubMed ID: 30309246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brief Report: Dapivirine Ring HIV-1 Prevention Effectiveness for Women Engaged in Vaginal and Anal Intercourse: Insights From Mathematical Modeling.
    Peebles K; Brown ER; Hendrix CW; Palanee-Phillips T; van der Straten A; Harkoo I; Reddy K; Mirembe BG; Jeenarain N; Hillier SL; Baeten JM; Barnabas RV;
    J Acquir Immune Defic Syndr; 2023 Feb; 92(2):122-126. PubMed ID: 36184755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.